Product Dev Landscape
Our drug candidates, ’1104 and ’1805, are in development to re-set the immune system from a pro-inflammatory state to a regulated homeostatic state to achieve superior long-term disease remission as compared to current therapies. The goal is to do this without suppressing the immune system so that it can function naturally as a protective host defense mechanism.
‘1104 has been shown to be safe and well tolerated in four clinical studies. Trialed in a Phase 2a study of Eosinophilic Esophagitis (EoE) ’1104 met its primary end point and caused a reduction in key inflammatory cells and an improvement in patient symptoms. We are preparing for the Phase 2b study based on these positive outcomes. ’1104 has also completed an allergen sensitivity Phase 2a trial with data pending. ’1805 has demonstrated a trend to remission of disease, which correlates with a reduction in the associated inflammatory biomarkers in rheumatoid arthritis in a Phase 2a study. In addition, both have demonstrated strong efficacy and safety in many preclinical studies to date.